Jeffrey Keats
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Lung Cancer Research Studies, Eosinophilic Disorders and Syndromes
Most-Cited Works
- → AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance(2009)1,234 cited
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML(2004)198 cited
- → Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen(2011)131 cited
- → AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes(2005)79 cited
- → Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases(2003)51 cited
- → Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)(2010)50 cited
- → Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC(2012)41 cited
- → Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors(2008)32 cited
- → Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)(2010)27 cited